AbCellera inks $515m deal to build antibody facility in Canada
The co-investment with the Governments of Canada and British Columbia will fund construction of antibody-based facilities to bolster capabilities and infrastructure. The CA$701 million ($515 million) investment aims to strengthen Canada’s capabilities and infrastructure for drug development, p ...
MilliporeSigma will invest €35 million ($37 million) in biosafety testing at its Stirling and Glasgow sites in Scotland.
MilliporeSigma – ...
The funding will support the launch of a CGT facility in Bristol, UK and cement the firm’s CDMO status, says eXmoor pharma.
Cell and gene th ...
Quality control issues have landed UCB Pharma a Form 483 following an inspection of its facilities in Braine-l'Alleud, Belgium.
UCB Pharma und ...
Sustainability initiatives are launching across the biopharmaceutical industry as companies begin to scrutinize their environmental impacts as pa ...
Recent Tweets
-
To everyone at #BiotechWeekBoston - thanks for a great event & see you next year!
8 months ago
-
@Dan5tanton hosting BioProcess Insider’s State of the Industry chat at the spotlight theater here at #BWB2022 https://t.co/UBCZCf1Jng
8 months ago
-
@ADaviesDHCG I couldn’t find a seat, it was so busy! A great talk with some really interesting and helpful talks ma… https://t.co/5b3mjes9tb
8 months ago
-
@ADaviesDHCG on stage at the Spotlight Theater discussing CGT capacity & demand #BWB2022 https://t.co/d5T0KYm7mp
8 months ago
